Targeting the Root Causes of Metabolic Disease w/ Bob Geho, Founder & CEO, Diasome

Episode notes

Send us Fan Mail Every year, one in five adults with Type 1 diabetes experiences a dangerous drop in blood sugar that renders them unable to treat themselves. These severe hypoglycemic events are still happening, even though many patients now use continuous glucose monitors and automated insulin pumps. Why has this trade-off between long-term A1C control and dangerous sugar crashes persisted for over 30 years? Bob Geho, Founder and CEO of Diasome, joins host David E. Williams to unpack the results of the company’s 200+ patient Phase 2B OPTI-2 trial of HDV™ insulin. The study was presented recently at the American Diabetes Association meeting in New Orleans. In the trial, five patients using standard insulin experienced severe hypoglycemic events. This compares with zero such events among patients receiving HDV™ insulin. Meanwhile, HDV™ insulin matched standard-of-care A1C control. Bob also shares how the HDV platform is being studied for its potential to reduce side effects in GLP-1 therapy and to address insulin resistance, considered the root cause of Type 2 Diabetes.

• GLP-1s May Reduce Cancer Progression16 / 100
• The Business & Science Behind the GLP-1 Boom44 / 100
• Why We Can Never Have Enough Doctors40 / 100
• The Future of Medicine Is Already Here w/ Bertalan Mesko, The Medical Futurist Institute
• Why Insulin Never Reaches the Liver